- Market Capitalization, $K 146,932
- Shares Outstanding, K 97,306
- Annual Sales, $ 0 K
- Annual Income, $ -26,130 K
- 60-Month Beta 0.97
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 3.24
|Period||Period Low||Period High||Performance|
| || |
-0.0700 (-4.27%)since 08/27/21
| || |
-0.9300 (-37.20%)since 06/25/21
| || |
-1.9200 (-55.01%)since 09/25/20
Precision (DTIL) signs an exclusive license agreement with Tiziana to explore the latter's fully human anti-CD3 mAb, foralumab, for treating various cancer indications. Stock up.
NEW YORK, NY / ACCESSWIRE / August 16, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tesla, Inc. ("Tesla" or the "Company") (NASDAQ:TSLA). Investors...
London, United Kingdom--(Newsfile Corp. - August 16, 2021) - (NASDAQ:TLSA) today announced that Dr. Kunwar Shailubhai, CEO & CSO will be attending the Q3 Virtual Investor Summit.
Tiziana (TLSA) reports positive data from a study investigating its anti-CD3 human monoclonal antibody, foralumab (nasally administered) for treating COVID-19 patients in Brazil. Shares up.
As of late, it has definitely been a great time to be an investor in Tiziana Life Sciences (TLSA).
Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
, /PRNewswire/ -- In the global lithium-ion power battery market, recent reports on total revenue numbers differ in size, but they agree that future revenues will increase and project a significant rise...
Companies In The News Are: TLSA, VIR, HEAR, CDMO
|3rd Resistance Point||1.7367|
|2nd Resistance Point||1.6633|
|1st Resistance Point||1.6167|
|1st Support Level||1.4967|
|2nd Support Level||1.4233|
|3rd Support Level||1.3767|